Stay updated on Mirvetuximab in Platinum-Sensitive Gynecologic Cancer Clinical Trial
Sign up to get notified when there's something new on the Mirvetuximab in Platinum-Sensitive Gynecologic Cancer Clinical Trial page.

Latest updates to the Mirvetuximab in Platinum-Sensitive Gynecologic Cancer Clinical Trial page
- Check5 days agoChange DetectedRevision: v3.4.3 is now displayed, replacing Revision: v3.4.2.SummaryDifference0.1%

- Check13 days agoChange DetectedThe two screenshots show only layout/UI adjustments with no changes to the study details or key data.SummaryDifference0.0%

- Check20 days agoChange Detected- No substantive content changes detected; core study information remains the same, with only layout and visual adjustments visible in the screenshots.SummaryDifference0.0%

- Check27 days agoChange DetectedFallopian tube cancer was added to the study conditions, and the Genetic and Rare Diseases Information Center resource was added.SummaryDifference0.1%

- Check34 days agoChange DetectedAdded Revision: v3.4.2 and removed the prior government-funding lapse notice (Revision: v3.4.1); no study data, eligibility criteria, or core page content were changed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check41 days agoChange DetectedA new site-wide notice has been added about the lapse in government funding and the NIH Clinical Center's operating status. The page revision has been updated from v3.4.0 to v3.4.1.SummaryDifference0.3%

Stay in the know with updates to Mirvetuximab in Platinum-Sensitive Gynecologic Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Mirvetuximab in Platinum-Sensitive Gynecologic Cancer Clinical Trial page.